Skip to main content
. 2018 Jun 19;9(47):28691–28701. doi: 10.18632/oncotarget.25611

Figure 1.

Figure 1

(A) Percentage of MMR IHC status for 996 Brazilian CRC patients; Positive IHC status: 88.9% (886/996), Negative IHC status: 10.2% (102/996) and Inconclusive IHC status 0.9% (8/996). (B) Percentage of molecular MSI status for 1013 Brazilian CRC patients; MSS (microsatellite stability): 85.8% (870/1013), MSI-L (low-microsatellite instability): 3.7% (37/1013) and MSI-H (high-microsatellite instability): 10.5% (106/1013).